PharmaFocus Today – media

2025 Wuzhen Health Conference | Tasly Achieves Multiple Awards, Driving a New Future of Medicine and Health with Innovation

From April 8th to 12th, 2025, Wuzhen, a water town in Jiangnan, welcomed the annual grand event in the field of medicine and health – Wuzhen Health Conference. This industry grand event, which gathers industry elites, experts, scholars, and well-known enterprises, is an important platform for gaining insights into industry trends and exchanging innovative ideas. Tianshili Pharmaceutical Group (hereinafter referred to as “Tianshili”) won multiple awards at the conference with innovative achievements in brand strategy, product positioning, market channels, and other aspects, becoming the focus of the audience. Brand Strategy Innovation: Shaping the Influence of Innovative Traditional Chinese Medicine Drugs In terms of brand strategy, Tasly always regards innovation as the core driving force and is committed to building a Chinese medicine brand with international influence. Winning the title of “VIP Strategic Cooperation Enterprise” at the 2025 Wuzhen Health Conference is a high recognition of its brand strength and ...
- Source: drugdu
- 34
- April 15, 2025
Boya Biotechnology plans to list and transfer 80% equity of its subsidiary; Two drugs from Hengrui Pharmaceutical have been approved for clinical trials | Medical Early Reference

NO.1 Boya Biotechnology plans to publicly list and transfer 80% equity of its subsidiary On April 13th, Boya Biotechnology announced its intention to transfer 80% equity of Jiangxi Boya Xinhe Pharmaceutical Co., Ltd. (referred to as “Boya Xinhe”) through listing on the Shanghai United Property Rights Exchange, with an initial listing amount of approximately 213 million yuan. Boya Xinhe was established in 2014, and its main business is the R&D, production and sales of anti infection, diabetes, cardio cerebrovascular drugs. After the equity transfer, the company holds 10.6869% of the equity of Boya Xinhe, and its wholly-owned subsidiary Jiangxi Boya Pharmaceutical Investment Co., Ltd. holds 9.3131% of the equity of Boya Xinhe. Boya Xi nhe will no longer be included in the company’s consolidated statements. Comment: From January to December 2024, Boya Xinhe’s operating revenue was 10.1729 million yuan, total profit was -34.6187 million yuan, and net profit was ...
- Source: drugdu
- 33
- April 15, 2025
Obtained drug clinical trial approval notice

Hengrui Medicine announced on the evening of April 13 that the company received the “Notice of Approval for Clinical Trial of Drugs” issued by the National Medical Products Administration for HRS-9190 for injection, and will conduct clinical trials in the near future. HRS-9190 for injection is a Class 1 new drug for intraoperative medication, used for tracheal intubation during the induction period of general anesthesia and maintaining skeletal muscle relaxation during surgery. The company announced on the same day that its subsidiaries Shanghai Hengrui Medicine Co., Ltd. and Suzhou Shengdia Biotechnology Co., Ltd. received the “Notice of Approval for Clinical Trial of Drugs” issued by the National Medical Products Administration for SHR-3792 injection, and will conduct clinical trials in the near future. SHR-3792 injection is an innovative anti-tumor drug candidate independently developed by the company, which has shown good anti-tumor activity in preclinical animal models. Upon inquiry, no similar drugs ...
- Source: drugdu
- 31
- April 15, 2025
Merck’s nine-valent HPV vaccine approved for marketing in China for male indications

On April 14, MerckAnnounced that Gardasil® 9 [9-valent human papillomavirus vaccine (crysogenyces cerevisiae)] (hereinafter referred to as “9-valent HPV vaccine”) has been approved for marketing by the National Medical Products Administration for multiple new indications, and is suitable for males aged 16 to 26. This approval makes Gardasil® 9 the first and currently the only 9-valent HPV vaccine approved in China for males and females of appropriate age. https://finance.eastmoney.com/a/202504143375989893.html
- Source: drugdu
- 32
- April 15, 2025
Servier’s “Oncology Business”

Recently, Servier spent $780 million to acquire BDTX-4933, a small molecule drug in Phase 1 clinical trials targeting RAS mutations and RAF changes in solid tumors, from Black Diamond Therapeutics. Today, Servier’s competitive position is threatened by challenges in the chronic disease drug market, and it is actively looking for a new way forward, with the latest goal of entering the field of oncology. In recent years, Servier has continuously strengthened its oncology pipeline through acquisitions and introductions, and has become a “dark horse” in the field of oncology treatment that cannot be underestimated. IDH inhibitor frontrunner Isocitrate dehydrogenase (IDH) is a key rate-limiting enzyme in the tricarboxylic acid cycle. There are three isoenzymes of IDHs, namely IDH1, IDH2 and IDH3. The functional loss caused by mutations in IDH1 and IDH2 will directly affect the product composition – α-ketoglutarate is converted into the carcinogenic metabolite 2-hydroxyglutarate, promoting the occurrence of ...
- Source: drugdu
- 29
- April 15, 2025
The world’s first new FcRn antagonist formulation is approved for marketing in the United States

Recently, Zai Lab’s partner argenx announced that the U.S. FDA (U.S. Food and Drug Administration) has officially approved the marketing of Efgartigimod prefilled subcutaneous injection formulation for the treatment of adult patients with generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) who are positive for acetylcholine receptor (AChR) antibodies. Efgartigimod is the world’s first approved FcRn antagonist. Previously, its intravenous formulation (IV) and subcutaneous formulation (SC) have been approved for marketing by the FDA (U.S. Food and Drug Administration). The approval of the prefilled subcutaneous injection formulation further enriches the product form of Efgartigimod and improves the convenience of patients’ medication. This not only consolidates Argenx’s leading position in the field of FcRn antagonists, but also brings new market opportunities to Zai Lab. As Agamod continues to expand in the global market, Zai Lab is expected to share its growth dividend in the field of rare diseases through ...
- Source: drugdu
- 30
- April 15, 2025
Midea Group established the Medical Division and released Midea Medical’s annual new products

On April 8, the 91st China International Medical Equipment Fair (CMEF) opened. During the exhibition, Midea Medical held the “AI All-dimensional Intelligent Transformation 2025 Midea Medical Annual New Product Release and China Backbone Guardian Plan Launch Meeting” and officially announced the establishment of Midea Medical Division. As one of the six major business sectors of Midea Group, Midea Medical is a major breakthrough in Midea Group’s diversified development strategy. Midea Medical has the accumulation of Wandong Medical in medical diagnostic equipment and intelligent imaging solutions, Kuka Medical’s cutting-edge technology in the field of surgical robots and rehabilitation robots, Midea Biomedical’s professional advantages in medical cold chain refrigeration, Swisslog Medical’s mature solutions in hospital logistics and pharmacy automation, and Midea Building Technology’s strength in the construction and operation of smart hospitals. The synergy of these advantageous resources will further enhance Midea Medical’s industrial competitiveness. Midea Medical will also rely on Midea ...
- Source: drugdu
- 47
- April 14, 2025
Operating income of 3.07 billion yuan in 2024, a year-on-year increase of 13.32%

The 2024 annual report recently released by Ruipu Bio shows that the company adheres to technological innovation and strategic layout, and achieves operating income of 3.07 billion yuan, a year-on-year increase of 13.32%; net profit attributable to shareholders of listed companies is 301 million yuan; it plans to pay 3 yuan (including tax) for every 10 shares. In 2024, the company invested 238 million yuan in research and development, accounting for 7.76% of operating income, and added 10 new veterinary drug registration certificates and 29 authorized patents. In the field of biological products, cutting-edge technologies such as mRNA technology platform and recombinant duck plague virus vector vaccine have made breakthroughs. Among them, the independently developed cat triple vaccine “Ruimiaoshu” has become the first local listed product. The enrofloxacin hydrochloride pellet coating preparation developed by the Drug Research Institute reduces the cost of medication by 25%-50%, which is highly recognized by ...
- Source: drugdu
- 42
- April 14, 2025
CanSino Biologics and Jiankai Technology have a strategic partnership to explore new mRNA vaccine tumor immunity solutions

On April 9, according to the official microblog of CanSino Biologics, CanSino Biologics (Shanghai) Co., Ltd., a subsidiary of CanSino Biologics, and Tianjin Jiankai Technology Co., Ltd. (hereinafter referred to as “Jiankai Technology”), a wholly-owned subsidiary of Jiankai Technology, recently signed a cooperative development agreement. The two parties will jointly promote the clinical research project of mRNA vaccines for the treatment of glioblastoma (GBM), and it is expected that the first patient will be dosed this year. https://finance.eastmoney.com/a/202504093371737123.html
- Source: drugdu
- 34
- April 14, 2025
Products will not be easily replaced, and the impact of tariffs is limited.

On April 8, local time, US President Trump delivered a speech saying that the United States will impose tariffs on drugs. This news has once again attracted market attention to pharmaceutical companies that were “exempted” in the previous round of tariff increases. From the market reaction on the 9th, the decline of individual stocks in the API sector was the largest. Data shows that 90% of active pharmaceutical ingredients (API) in the US market rely on imports, of which 60% come from China. In the short term, API companies that rely on US export business may be affected by the tax increase, but in the long term, the tax increase on imported APIs may cause a surge in the cost of US pharmaceutical research and development and manufacturing. Industry insiders believe that US tariffs mainly have a certain impact on the low-end pharmaceutical industry, and have little impact on the ...
- Source: drugdu
- 34
- April 14, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.